title: Thromboembolic disease and cancer: possible new treatments.
abstract: Hypoxia-induced endothelin (ET) and vascular endothelial growth or permeability factor (VEGF) play an important role in tumor biology by promoting angiogenesis. Angiogenesis alters hemostasis and promotes thromboembolic disease (TED). Therapeutic angiogenesis directed against ET and VEGF may reduce the incidence of TED in cancer patients.
authors.affiliation: Department of Physiology and Biophysics, School of Nursing and Health Studies, Georgetown University, Washington, DC, USA.
authors.forename: Allan D
authors.initials: AD
authors.lastname: Angerio
authors.forename: Dorothy A
authors.initials: DA
authors.lastname: Fink
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000451:nursing; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000188:drug therapy* / Q000451:nursing; D024802:Nurse's Role; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors; D013923:Thromboembolism / Q000150:complications / Q000188:drug therapy* / Q000451:nursing*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D005343:Fibrinolytic Agents